MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-25-3771

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Guercio Brendan J, Pietzak Eugene J, Ravichandran Vignesh, Chen Jie-Fu, Shah Ronak H, Peters Vanessa, Regazzi Ashley M, Niglio Scot A, Aggen David H, Funt Samuel A, Donahue Timothy F, Goh Alvin C, Cha Eugene K, Wong Phillip, Richards Allison L, Cobbs Cassidy C, Donat S Machele, Dalbagni Guido, Bochner Bernard H, Iyer Gopa, Donoghue Mark T A, Ostrovnaya Irina, Al-Ahmadie Hikmat A, Rosenberg Jonathan E, Teo Min Yuen

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

PURPOSE: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients.

PATIENTS AND

METHODS

Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset.

RESULTS

Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2's failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61-100] and 61% with ipilimumab/nivolumab (95% CI, 39-95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022).

CONCLUSIONS

Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.

Для цитирования: Guercio Brendan J, Pietzak Eugene J, Ravichandran Vignesh, Chen Jie-Fu, Shah Ronak H, Peters Vanessa, Regazzi Ashley M, Niglio Scot A, Aggen David H, Funt Samuel A, Donahue Timothy F, Goh Alvin C, Cha Eugene K, Wong Phillip, Richards Allison L, Cobbs Cassidy C, Donat S Machele, Dalbagni Guido, Bochner Bernard H, Iyer Gopa, Donoghue Mark T A, Ostrovnaya Irina, Al-Ahmadie Hikmat A, Rosenberg Jonathan E, Teo Min Yuen. Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. DOI: 10.1158/1078-0432.ccr-25-3771.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.